These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12194173)

  • 41. Regulations implementing the Federal Coal Mine Health and Safety Act of 1969, as amended. Employment Standards Administration, Labor. Final rule.
    Fed Regist; 2000 Dec; 65(245):79920-80107. PubMed ID: 11503734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medicaid program; time limitation on record keeping requirements under the drug rebate program. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Jan; 69(3):508-14. PubMed ID: 14968795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medicare program; changes to the Medicare claims appeal procedures; continuation of effectiveness and extension of timeline for publication of final rule. Interim final rule with comment period; continuation of effectiveness and extension of timeline for publication of final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Feb; 74(38):8867-8. PubMed ID: 19418637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2001 Aug; 66(159):42943-4. PubMed ID: 11794309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medicare program; Medicare prescription drug benefit; interpretation. Final rule; interpretation.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Mar; 70(53):13397-400. PubMed ID: 15786588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2009 May; 74(97):23790-3. PubMed ID: 19507329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preventing the accumulation of surplus controlled substances at long term care facilities. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 May; 70(92):25462-6. PubMed ID: 15892213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicaid program and State Children's Health Insurance Program (SCHIP) payment error rate measurement. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Oct; 70(192):58259-77. PubMed ID: 16206427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implementation of the Methamphetamine Production Prevention Act of 2008. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2011 Dec; 76(231):74696-9. PubMed ID: 22145189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration. Notice of proposed rulemaking.
    Fed Regist; 1982 Sep; 47(181):41140. PubMed ID: 10262071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-drug program for personnel engaged in specified aviation activities--Federal Aviation Administration. Final rule.
    Fed Regist; 1991 Sep; 56(172):43974-6. PubMed ID: 10170821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Schedules of controlled substances; exempt anabolic steroid products. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Mar; 73(52):14178-9. PubMed ID: 18464343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infectious substances--DOT. Final rule.
    Fed Regist; 1995 Sep; 60(182):48780-7. PubMed ID: 10151186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.